ReviewBreast cancer research : BCR2020
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
Review in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660083 (Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer), which is not on this map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it, 220 citations in OpenAlex.
- Breast conservation versus mastectomy for metaplastic breast cancer: A systematic review and meta-analysis.Asia-Pacific journal of clinical oncology · 2025Pooled it
- Development and validation of competitive risk model for older women with metaplastic breast cancer.BMC women's health · 2023Trial
- A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Computational Identification of New Dual PAK4 and NAMPT Inhibitors.International journal of molecular sciences · 2026Article
- Germline BRCA2 Pathogenic Variant in Metaplastic Breast Carcinoma with Heterologous Mesenchymal Differentiation: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Triple-Negative Inflammatory Metaplastic Breast Cancer Presenting as a Non-Mass Lesion.Journal of medical cases · 2026Article
- NOS2 and COX2 impact the spatial landscape of CD8Redox biology · 2026Review
- Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer.British journal of cancer · 2026Article
- Intratumor heterogeneity in human basal like breast cancer is revealed by single cell molecular subtyping.Communications medicine · 2026Article
- A case of metaplastic breast cancer presenting as a fungating breast wound.Journal of surgical case reports · 2026Article
- Neoplastic Immune Mimicry Potentiates Breast Tumor Progression.Cancer research · 2026Article
- Single-cell transcriptomics uncover RNF130-mediated TNF-α pathway activation and worenine synergy with paclitaxel in breast cancer.Clinical epigenetics · 2026Article
- Metaplastic Breast Cancer Characteristics and Patterns of Recurrence: A Single Institution Experience.Cureus · 2026Article
- Clinical Outcomes and Treatment-Related Complications in Triple-Negative Breast Cancer: A Review of 24 Case Reports from 2020 to 2025.Therapeutics and clinical risk management · 2026Review
- Integrative systematic review and transcriptomic -machine learning analysis of molecular signatures in metaplastic breast cancer.Ecancermedicalscience · 2026Article
- Metaplastic breast cancer: a clinicopathological analysis of nine cases highlighting diagnostic challenges and aggressive behavior.Frontiers in oncology · 2026Article
- Subtype-specific sonographic signatures and clinicopathological features of metaplastic breast cancer: a 50-case cohort study.Frontiers in medicine · 2026Article
- Metaplastic breast carcinoma versus triple-negative breast cancer: distinct metastatic patterns and inferior overall survival in a matched retrospective cohort study.Frontiers in oncology · 2026Article
- Evaluation of Metaplastic Triple-Negative Breast Cancer Extracellular Matrix Structure and Protein Composition.Bioengineering (Basel, Switzerland) · 2025Article
- The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications.Current issues in molecular biology · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, typically epithelial and mesenchymal components. This variant harbors a triple-negative breast cancer (TNBC) phenotype, yet has a worse prognosis and decreased survival compared to TNBC. There are currently no standardized treatment guidelines specifically for MpBC. However, prior studies have found that MpBC typically has molecular alterations in epithelial-to-mesenchymal transition, amplification of epidermal growth factor receptor, PI3K/Akt signaling, nitric oxide signaling, Wnt/β-catenin signaling, altered immune response, and cell cycle dysregulation. Some of these molecular alterations have been studied as therapeutic targets, in both the preclinical and clinical setting. This current review discusses the histological organization and cellular origins of MpBC, molecular alterations, the role of radiation therapy, and current clinical trials for MpBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.